The NINDS Parkinson's disease biomarkers program

Movement Disorders

Volumn 31, Issue 6, 2016, Pages 915-923

  Rosenthal, Liana S ^a   Drake, Daniel ^b   Alcalay, Roy N ^b   Babcock, Debra ^c   Bowman, F Dubois ^b   Chen Plotkin, Alice ^d   Dawson, Ted M ^a   Dewey, Richard B ^e   German, Dwight C ^f   Huang, Xuemei ^g   Landin, Barry ^h   Mcauliffe, Matthew ^h   Petyuk, Vladislav A ⁱ   Scherzer, Clemens R ^j   Hillaire Clarke, Coryse St ^c   Sieber, Beth Anne ^c   Sutherland, Margaret ^c   Tarn, Chi ^k   West, Andrew ^l   Vaillancourt, David ^m   Zhang, Jing ⁿ   Gwinn, Katrina ^c   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k Laboratory of Molecular and Cellular Biology of Hematopoiesis   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m UNIVERSITY OF FLORIDA   (United States)

ⁿ UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

Biofluids; Data management; Disease modifying strategies; Parkinsonism

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; GLUCOSYLCERAMIDASE; HEMOGLOBIN; LEUCINE RICH REPEAT KINASE 2; NEUROMELANIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COHORT ANALYSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DOPAMINERGIC SYSTEM; ESSENTIAL TREMOR; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEMOGLOBIN DETERMINATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; MULTICENTER STUDY (TOPIC); NATIONAL HEALTH ORGANIZATION; PROGRAM DEVELOPMENT; UNITED STATES;

BIOMARKERS; HUMANS; MULTICENTER STUDIES AS TOPIC; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (U.S.); PARKINSON DISEASE; PROGRAM DEVELOPMENT; UNITED STATES;

EID: 84949871151     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26438     Document Type: Article

References (16)

1. Atkinson AJ, Colburn WA, DeGruttola G, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacol Ther 2001;69:89-95.
2. Mohammadi D. The Harvard Biomarker Study's big plan. Lancet Neurol 2013;12:739-740.
3. Nalls MA, Bras J, Hernandez DG, et al. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging 2015;36:1605.
4. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014;46:989-993.
5. Ferrari R, Hernandez DG, Nalls MA, et al. Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol 2014;13:686-699.
6. Chen-Plotkin Alice S, Hu William T, Siderowf Andrew, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011;69:655-663.
7. Qiang Judy K, Wong Yvette C, Siderowf Andrew, et al. Plasma apolipoprotein A1 as a biomarker for Parkinson's disease. Ann Neurol 2013;74:119-127.
8. Mancini M, King L, Salarian A, Holmstrom L, McNames J, Horak FB. Mobility lab to assess balance and gait with synchronized body-worn sensors. J Bioeng Biomed Sci 2011;(Suppl 1):007.
9. Dewey DC, Miocinovic S, Bernstein I, et al. Automated gait and balance parameters diagnose and correlate with severity in Parkinson disease. J Neurol Sci 2014;345:131-138.
10. Ofori E, Pasternak O, Planetta PJ, et al. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease. Brain 2015;138:2322-2331.
11. Spraker MB, Prodoehl J, Corcos DM, Comella CL, Vaillancourt DE. Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease. Hum Brain Mapp 2010;31:1928-1941.
12. Alcalay RN, Diner T, Quinn T, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 2014;71:752-757.
13. Alcalay RN, Levy O, Waters C, et al. Glucocerebrosidase activity in Parkinson disease with and without GBA Mutations. Brain 2015; DOI: http://dx.doi.org/10.1093/brain/awv179
14. Shi T1, Fillmore TL, Sun X, et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci U S A 2012;109:15395-15400.
15. Ziegler DA, Ashourian P, Wonderlick JS, et al. Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms. Scand J Psychol 2014;55:278-286.
16. Ding H, Dhima K, Lockhart KC, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease. Neurology 2013;81:1531-1537.